Macrocyclic lactones and uses thereof as modulators of purinergic receptors
Described herein, inter alia, are macrocyclic lactones such as ivermectin and methods for their use in treating, for example, hyperproliferative disorders such as cancer.
1. A method of treating breast cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a macrocyclic lactone, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an anti-cancer immunostimulant, wherein the macrocyclic lactone is ivermectin and the anti-cancer immunostimulant is a PD-1 inhibitor or a PD-L1 inhibitor.
2. The method of claim 1 , wherein the cancer is triple negative breast cancer.
3. The method of claim 1 , wherein the anti-cancer immunostimulant is a PD-1 inhibitor.
4. A pharmaceutical composition comprising a macrocyclic lactone, or pharmaceutically acceptable salt thereof, a second agent, and a pharmaceutically acceptable excipient, wherein the macrocyclic lactone is ivermectin and the second agent is a PD-1 inhibitor or a PD-L1 inhibitor; and
wherein the macrocyclic lactone is present in a therapeutically effective amount to treat breast cancer and the second agent is present in a therapeutically effective amount to treat breast cancer.
5. The pharmaceutical composition of claim 4 , wherein the second agent is a PD-1 inhibitor.